Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia

Author:

Cheng Ying1ORCID,Yang James Chih-Hsin2,Okamoto Isamu3,Zhang Li4,Hu Jie5,Wang Donglin6,Hu Chengping7,Zhou Jianying8,Wu Lin9,Cao Lejie10,Liu Jiwei11,Zhang Helong12,Sun Hong13,Wang Ziping14,Gao Hongjun15,Yan Yan16,Xiao Suijun16,Lin Jianxin17,Pietanza M. Catherine17,Kurata Takayasu18

Affiliation:

1. Jilin Cancer Hospital, Chaoyang Borough, Changchun, 130012, China

2. National Taiwan University Hospital & National Taiwan University Cancer Center, 106, Taipei, China

3. Kyushu University Hospital, Fukuoka, 812-8582, Japan

4. Peking Union Medical College Hospital, Beijing, 100730, China

5. Zhongshan Hospital Fudan University, Shanghai Geriatric Center, Shanghai, 200032, China

6. Chongqing Cancer Hospital, Chongqing, 400030, China

7. Xiangya Hospital Central South University, Changsha, 410008, China

8. The First Affiliated Hospital of Zhejiang University, Hangzhou, 310003, China

9. Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China

10. The First Affiliated Hospital of University of Science & Technology of China (Anhui Provincial Hospital), Hefei, 230001, China

11. The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China

12. Tang Du Hospital, The Fourth Military Medical University, Xi'an, 710038, China

13. The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, 710061, China

14. Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, China

15. Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, China

16. MSD China, Shanghai, 200233, China

17. Merck & Co., Inc., Rahway, NJ 07065, USA

18. Kansai Medical University Hospital, Osaka, 573-1010, Japan

Abstract

Aim: We pooled patient-level data from three randomized controlled studies to evaluate the combination of pembrolizumab plus chemotherapy in patients with untreated advanced/metastatic non-small-cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) tumor proportion score <1% in East Asia. Methods: The analysis included 107 patients from China, Japan, Korea, Thailand and Taiwan (pembrolizumab plus chemotherapy, n = 56; chemotherapy alone, n = 51). Results: For pembrolizumab plus chemotherapy versus chemotherapy alone, median overall survival was 21.3 versus 12.6 months (HR, 0.55 [95% CI: 0.35–0.87]) and median progression-free survival was 8.4 versus 6.0 months (HR, 0.64 [95% CI: 0.43–0.96]). Conclusion: The analysis supports the use of pembrolizumab in combination with platinum-based chemotherapy for East Asian patients with PD-L1-negative, advanced NSCLC.

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Reference44 articles.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3